258 related articles for article (PubMed ID: 32667108)
1. Japanese Society of Medical Oncology Clinical Guidelines: Molecular Testing for Colorectal Cancer Treatment, 4th edition.
Ebi H; Bando H; Taniguchi H; Sunakawa Y; Okugawa Y; Hatanaka Y; Hosoda W; Kumamoto K; Nakatani K; Yamazaki K
Cancer Sci; 2020 Oct; 111(10):3962-3969. PubMed ID: 32667108
[TBL] [Abstract][Full Text] [Related]
2. Japanese Society of Medical Oncology clinical guidelines: Molecular testing for colorectal cancer treatment, 5th edition.
Bando H; Yamaguchi K; Mitani S; Sawada K; Mishima S; Komine K; Okugawa Y; Hosoda W; Ebi H
Cancer Sci; 2024 Mar; 115(3):1014-1021. PubMed ID: 38263580
[TBL] [Abstract][Full Text] [Related]
3. Japanese Society of Medical Oncology Clinical Guidelines: Molecular Testing for Colorectal Cancer Treatment, Third Edition.
Yamazaki K; Taniguchi H; Yoshino T; Akagi K; Ishida H; Ebi H; Nakatani K; Muro K; Yatabe Y; Yamaguchi K; Tsuchihara K
Cancer Sci; 2018 Jun; 109(6):2074-2079. PubMed ID: 29873882
[TBL] [Abstract][Full Text] [Related]
4. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
[TBL] [Abstract][Full Text] [Related]
5. CIRCULATE-Japan: Circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer.
Taniguchi H; Nakamura Y; Kotani D; Yukami H; Mishima S; Sawada K; Shirasu H; Ebi H; Yamanaka T; Aleshin A; Billings PR; Rabinowitz M; Oki E; Takemasa I; Kato T; Mori M; Yoshino T
Cancer Sci; 2021 Jul; 112(7):2915-2920. PubMed ID: 33931919
[TBL] [Abstract][Full Text] [Related]
6. Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer.
Hampel H; Pearlman R; Beightol M; Zhao W; Jones D; Frankel WL; Goodfellow PJ; Yilmaz A; Miller K; Bacher J; Jacobson A; Paskett E; Shields PG; Goldberg RM; de la Chapelle A; Shirts BH; Pritchard CC;
JAMA Oncol; 2018 Jun; 4(6):806-813. PubMed ID: 29596542
[TBL] [Abstract][Full Text] [Related]
7. Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancer.
Kloth M; Ruesseler V; Engel C; Koenig K; Peifer M; Mariotti E; Kuenstlinger H; Florin A; Rommerscheidt-Fuss U; Koitzsch U; Wodtke C; Ueckeroth F; Holzapfel S; Aretz S; Propping P; Loeffler M; Merkelbach-Bruse S; Odenthal M; Friedrichs N; Heukamp LC; Zander T; Buettner R
Gut; 2016 Aug; 65(8):1296-305. PubMed ID: 26001389
[TBL] [Abstract][Full Text] [Related]
8. RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancer.
van Helden EJ; Angus L; Menke-van der Houven van Oordt CW; Heideman DAM; Boon E; van Es SC; Radema SA; van Herpen CML; de Groot DJA; de Vries EGE; Jansen MPHM; Sleijfer S; Verheul HMW
Mol Oncol; 2019 Nov; 13(11):2361-2374. PubMed ID: 31350822
[TBL] [Abstract][Full Text] [Related]
9. Circulating tumour DNA, a promising biomarker for the management of colorectal cancer.
Khakoo S; Georgiou A; Gerlinger M; Cunningham D; Starling N
Crit Rev Oncol Hematol; 2018 Feb; 122():72-82. PubMed ID: 29458792
[TBL] [Abstract][Full Text] [Related]
10. BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment?
Cohen R; Cervera P; Svrcek M; Pellat A; Dreyer C; de Gramont A; André T
Curr Treat Options Oncol; 2017 Feb; 18(2):9. PubMed ID: 28214977
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of BRAF V600E mutation and microsatellite instability in Japanese patients with sporadic colorectal cancer.
Nakaji Y; Oki E; Nakanishi R; Ando K; Sugiyama M; Nakashima Y; Yamashita N; Saeki H; Oda Y; Maehara Y
J Cancer Res Clin Oncol; 2017 Jan; 143(1):151-160. PubMed ID: 27672042
[TBL] [Abstract][Full Text] [Related]
12. Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Colorectal Cancer: Implications for Response and Resistance to Targeted Therapeutics.
Choi IS; Kato S; Fanta PT; Leichman L; Okamura R; Raymond VM; Lanman RB; Lippman SM; Kurzrock R
Mol Cancer Ther; 2019 Oct; 18(10):1852-1862. PubMed ID: 31320401
[TBL] [Abstract][Full Text] [Related]
13. Molecular testing for Lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation.
Snowsill T; Coelho H; Huxley N; Jones-Hughes T; Briscoe S; Frayling IM; Hyde C
Health Technol Assess; 2017 Sep; 21(51):1-238. PubMed ID: 28895526
[TBL] [Abstract][Full Text] [Related]
14. Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with DNA mismatch repair deficient (dMMR) tumors, third edition.
Mishima S; Naito Y; Akagi K; Hayashi N; Hirasawa A; Hishiki T; Igarashi A; Ikeda M; Kadowaki S; Kajiyama H; Kato M; Kenmotsu H; Kodera Y; Komine K; Koyama T; Maeda O; Miyachi M; Nishihara H; Nishiyama H; Ohga S; Okamoto W; Oki E; Ono S; Sanada M; Sekine I; Takano T; Tao K; Terashima K; Tsuchihara K; Yatabe Y; Yoshino T; Baba E
Int J Clin Oncol; 2023 Oct; 28(10):1237-1258. PubMed ID: 37599324
[TBL] [Abstract][Full Text] [Related]
15. Screening for Lynch Syndrome in Young Colorectal Cancer Patients from Saudi Arabia Using Microsatellite Instability as the Initial Test.
Alqahtani M; Grieu F; Carrello A; Amanuel B; Mashour M; Alattas R; Alsaleh K; Alsheikh A; Alqahtani S; Iacopetta B
Asian Pac J Cancer Prev; 2016; 17(4):1917-23. PubMed ID: 27221876
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of Lynch syndrome in a Middle Eastern population with colorectal cancer.
Siraj AK; Prabhakaran S; Bavi P; Bu R; Beg S; Hazmi MA; Al-Rasheed M; Al-Assiri M; Sairafi R; Al-Dayel F; Al-Sanea N; Uddin S; Al-Kuraya KS
Cancer; 2015 Jun; 121(11):1762-71. PubMed ID: 25712738
[TBL] [Abstract][Full Text] [Related]
17. Advances in the therapy of BRAF
Jin Z; Sinicrope FA
Expert Rev Anticancer Ther; 2019 Sep; 19(9):823-829. PubMed ID: 31455117
[No Abstract] [Full Text] [Related]
18. Fusion Kinases Identified by Genomic Analyses of Sporadic Microsatellite Instability-High Colorectal Cancers.
Sato K; Kawazu M; Yamamoto Y; Ueno T; Kojima S; Nagae G; Abe H; Soda M; Oga T; Kohsaka S; Sai E; Yamashita Y; Iinuma H; Fukayama M; Aburatani H; Watanabe T; Mano H
Clin Cancer Res; 2019 Jan; 25(1):378-389. PubMed ID: 30279230
[TBL] [Abstract][Full Text] [Related]
19. High concordance rate of KRAS/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases.
Fujiyoshi K; Yamamoto G; Takahashi A; Arai Y; Yamada M; Kakuta M; Yamaguchi K; Akagi Y; Nishimura Y; Sakamoto H; Akagi K
Oncol Rep; 2017 Feb; 37(2):785-792. PubMed ID: 28000889
[TBL] [Abstract][Full Text] [Related]
20. Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer.
Rankin A; Klempner SJ; Erlich R; Sun JX; Grothey A; Fakih M; George TJ; Lee J; Ross JS; Stephens PJ; Miller VA; Ali SM; Schrock AB
Oncologist; 2016 Nov; 21(11):1306-1314. PubMed ID: 27682134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
